Infliximab: A review of its use in Crohn's disease and rheumatoid arthritis

BioDrugs

Volumn 10, Issue 5, 1998, Pages 397-422

  Onrust, Susan V ^a   Lamb, Harriet M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHIMERIC ANTIBODY; DNA ANTIBODY; DRUG ANTIBODY; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0031759597     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199810050-00006     Document Type: Review

References (96)

1. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody Mol Immunol 1993; 30(16): 1443-53
2. Siegel SA, Shealy DJ, Nakada MT. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995 Jan: 7 (1): 15-25
3. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNFα monoclonal antibody cA2 binds recombinant transmembrane INFα and activates immune effector functions. Cytokine 1995 Apr; 7 (3): 251-9
4. Donaldson Jr RM. Crohn's disease. In: Sleisenger MH, Fordtran JS, editors. Gastrointestinal disease: pathophysiology, diagnosis, management. 4th ed. v. 2. Philadelphia: W.B. Saunders Company, 1989: 1327-58
5. Lipsky PE. Rheumatoid arthritis. In: Wilson JE, Braunwald E, Isselbacher, editors. Harrison's principles of internal medicine. 12th ed. v. 2. New York: McGraw-Hill, Inc., 1991: 1437-43
6. Starkebaum G. Role of cytokines in rheumatoid arthritis. Sci Med 1998 Mar-Apr: 5: 6-15
7. van Deventer SJH, Camoglio L. Monoclonal antibody therapy of inflammatory bowel disease. Aliment Pharmacol Ther 1996; 10 Suppl. 2: 107-11
8. Weckmann AL, Alcocer-Varela J. Cytokine inhibitors in autoimmune disease. Semin Arthritis Rheum 1996 Oct; 26: 539-57
9. Eigler A, Sinha B, Hartmann G, et al. Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 1997 Oct; 18: 487-92
10. Dinarello CA. Role of pro- and anti-inflammatory cytokines during inflammation: experimental and clinical findings. J Biol Regul Homeost Agents 1997 Jul-Sep; 11: 91-103
11. van Deventer SJH. Tumour necrosis factor and Crohn's disease. Gut 1997; 40: 443-8
12. Sartor RB. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 1997 Dec; 92 (12) Suppl. 1: 5S-11S
13. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440
14. Radford-Smith G, Jewell DP. Cytokines and inflammatory bowel disease. Baillieres Clin Gastroenterol 1996 Mar; 10(1): 151-64
15. Mantovani A. The interplay between primary and secondary cytokines: cytokines involved in the regulation of monocyte recruitment. Drugs 1997; 54 Suppl. 1: 15-23
16. Szekanecz Z, Koch AE, Kunkel SL, et al. Cytokines in rheumatoid arthritis: potential targets for pharmacological intervention. Drugs Aging 1998 May; 12 (5): 377-90
17. Feldmann M, Elliott MJ, Woody JN, et al. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. Advances in Immunology 1997; 64: 283-350
18. Dalesandro MR, Kinney CS, Frederick B, et al. Potential clinical relevance of the mechanism of inhibition of immune function by the mouse/human chimeric anti-TNFα antibody, cA2 [abstract]. Arthritis Rheum 1995 Sep; 38 Suppl.: S401
19. Radema SA, van Dullemen JM, Tytgat GNJ, et al. Decreased production of chemokines in patients with Crohns disease after anti-TNF therapy [abstract]. Clin Immunol Immunopathol 1995 Jul; 76 (Pt 2): 45
20. Tak PP, Taylor C, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor-α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996 Jul; 39: 1077-81
21. Paleolog EM, Hunt M, Elliot MJ, et al. Deactivation of vascular endothelium by monoclonal anti-tumour necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 1996 Ju; 39: 1082-91
22. Baert F, Peeters M, P'Haens G, et al. Impressive histologic improvement after TNF antibody (cA2) therapy in active Crohn's disease [abstract]. Gut 1996; 39 Suppl. 1: A17
23. Shealy D, Mace K, DeWoody K. Reduction in serum VEGF and sICAM-I are associated with clinical response to anti-TNF therapy in patients with severe Crohn's disease [abstract]. Gastroenterology 1997; 112 (4): A1090
24. Lorenz H-M, Antoni C, Valerius T, et al. In vivo blockade of TNFα by intravenous infusion of a chimeric monoclonal TNFα antibody in patients with rheumatoid arthritis: short tem cellular and molecular effects. J Immunol 1996 Feb 15; 156: 1646-53
25. van Dullemen HM, van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995 Jul; 109: 129-35
26. Taylor PC, Chapman P, Elliott MJ, et al. Reduced granulocyte traffic and chemotactic gradients in rheumatoid joints following anti-TNFα therapy [abstract]. Arthritis Rheum 1997 Sep; 40 Suppl.: S8O
27. Plevy SE, Landers CJ, Prehn J, et al. A role for TNFα and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol 1997; 159: 6276-82
28. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α. Arthritis Rheum 1993 Dec; 36: 1681-90
29. Lorenz H-M, Hieronymus T, Grünke M, et al. In vivo blockade of TNFα patients with rheumatoid arthritis: indication for tachyphylaxis in long term ex vivo and in vitro effects after repeated infusion of chimeric monoclonal antibody cA2 [abstract]. Arthritis Rheum 1996 Sep; 39 Suppl.: S244
30. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997 Oct 9; 337: 1029-35
31. Targan SR, Schaible TF. Chimeric monoclonal antibody cA2 to tumor necrosis factor-alpha for Crohn's disease. Reply [letter]. N Engl J Med 1998 Jan 29; 338: 334
32. Meenan J, Hommes DW, van Dullemen H, et al. The influence of TNFα mAb, cA2, on circulating lymphocyte populations [abstract]. Gastroenterology 1997 Apr; 112 Suppl.: A1039
33. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A 1989 Jun; 86: 4220-4
34. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor-α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994 Oct 22; 344: 1105-10
35. Charles PJ, Elliott MJ, Feldmann M, et al. Development of anti dsDNA antibodies in patients with rheumatoid arthritis treated with a chimeric monoclonal antibody to TNFα [abstract]. Rheumatol Eur 1995; 24 Suppl. 3: 108
36. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor-α (cA2) in patients with rheumatoid arthritis. Lancet 1994 Oct 22; 344: 1125-7
37. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998 Sep; 41 (9): 1552-63
38. Janeway Jr CA, Travers P, editors. Immunobiology: the immune system in health and disease. London: Current Biology, Ltd., 1994
39. Centocor Inc. Remicade (infliximab) for IV injection prescribing information for USA. 12 Aug 1998 (Data on file)
40. Hahn BH. Systemic lupus erythematosus. In: Wilson JD, Braunwald E, Isselbacher KJ, editors. Principles of internal medicine. 12th ed. v. 2. Now York: McGraw-Hill, Inc., 1991: 1432-7
41. Barland P, Lipstein E. Selection and use of laboratory tests in the rheumatic diseases. Am J Med 1996 Feb 26; 100 Suppl. 2A: 16S-23S
42. Folwaczny C, Noehl N, Endres SP, et al. Antinuclear autoantibodies in patients with inflammatory bowel disease: high prevalence in first-degree relatives. Dig Dis Sci 1997 Aug; 42 (8): 1593-7
43. Maini RN, Elliott MJ, Long-Fox A, et al. Clinical response of rheumatoid arthritis (RA) to anti-TNFα (cA2) monoclonal antibody (mab) is related to administered dose and persistence of circulating antibody [abstract]. Arthritis Rheum 1995 Sep; 38 Suppl.: S186
44. Maini RN, Breedveld FC, Kalden JR, et al. Sustained therapeutic efficacy of multiple intravenous infusions of anti-TNFα monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. 1998, Centocor Inc. (Data on file)
45. Rutgeerts P, D'Haens G, van Deventer SJH, et al. Retreatment with anti-TNFα chimeric antibody (cA2) effectively maintains cA2-induced remission in Crohn's disease [abstract]. Gastroenterology 1997 Apr; 112 Suppl.: A1078
46. Present D, Mayer L, van Deventer SJH, et al. Anti-TNF-alpha chimeric antibody (cA2) is effective in the treatment of the fistulae of Crohn's disease: a multicenter, randomized, double-blind, placebo-controlled study [abstract]. Am J Gastroenterol 1997 Sep; 92: 1746
47. McCabe RP, Woody J, van Deventer S, et al. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease [abstract]. Gastroenterology 1996 Apr; 110 Suppl.: A962
48. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's Disease Activity Index: National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44
49. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994; 106: 287-96
50. Guyatt GH, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989; 96: 804-10
51. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Clin 1984; 10: 983-9
52. Kavanaugh AF, Cush JJ, St Clair EW, et al. Anti-TNFα monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX): results of a double-blind, placebo-controlled multicenter trial [abstract]. Arthritis Rheum 1996 Sep; 39 Suppl.: S123
53. Kavanaugh AF, Cush JJ, St Clair EW, et al. Anti-TNFα monoclonal antibody (mAb) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX): results of open label, repeated dose administration following a single dose double-blind, placebo controlled trial [abstract]. Arthritis Rheum 1996 Sep; 39 Suppl.: S244
54. Arnett FC, Edworthy SM, Bloch DA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988 Mar; 31 (3): 315-24
55. Mallya RK, Mace BEW. The assessment of disease activity in rheumatoid arthritis using a multivariate analysis. Rheumatology and Rehabilitation 1981; 20: 14-7
56. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140: 659-62
57. Paulus HE, Egger MJ, Ward JR, et al. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990 Apr; 33 (4): 477-84
58. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995 Jun; 38 (6): 727-35
59. Boers M. International consensus on which measures to use in rheumatoid arthritis clinical trials. Neth J Med 1993 Aug; 43: 55-8
60. Kalden-Nemeth D, Grebmeier J, Antoni C, et al. NMR monitoring of rheumatoid arthritis patients receiving anti-TNFα monoclonal antibody therapy. Rheumatol Int 1997 Mar; 16: 249-55
61. St Clair EW, Gordon B, Turkington TG, et al. Quantitative assessment of the therapeutic response to chimeric anti-TNF in rheumatoid arthritis (RA) by positron emission tomography (PET) [abstract]. Arthritis Rheum 1996 Sep; 39 Suppl.: S243
62. Centocor Inc. Characteristics of infliximab treated patients with lymphoproliferative disorders. (Data on file)
63. Kvist N, Jacobsen O, Norgaard P, et al. Malignancy in Crohn's disease. Scand J Gastroenterol 1986 Jan; 21 (1): 82-6
64. Nakajima H, Munakata A, Yoshida Y, et al. Extraintestinal cancers in Crohn's disease. Digestion 1990; 47 (1): 1-7
65. Geboes K. Cancer and its prevention. Eur J Gastroenterol Hepatol 1994; 6 (2): 117-20
66. Greenstein AJ, Mullin GE, Strauchen JA, et al. Lymphoma in inflammatory bowel disease. Cancer 1992; 69: 1119-23
67. Baecklund E, Ekbom A, Sparén P, et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ 1998 Jul; 317: 180-1
68. Jones M, Symmons D, Finn J, et al. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996; 35: 738-45
69. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997; 40 (9): 1580-6
70. Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996; 32A (10): 1753-7
71. Hanauer SB, Meyers S. Management of Crohn's disease in adults. Am J Gastroenterol 1997 Apr; 92: 559-66
72. Pincus T. The underestimated long term medical and economic consequences of rheumatoid arthritis. Drugs 1995; 50 Suppl. 1: 1-14
73. Gremillion RB, van Vollenhoven RF. Rheumatoid arthritis: designing and implementing a treatment plan. Postgrad Med 1998 Feb; 103 (2): 103-6
74. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996 May; 39 (5): 713-22
75. Sandhorn WJ, Van Os EC, Zins BJ, et al. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995; 109: 1808-17
76. Modigliani R. Chronic active Crohn's disease: an update on prevention and treatment. Res Clin Forum 1998; 20: 169-77
77. Borley NR, Mortensen NJ, Jewell DP. Preventing postoperative recurrence of Crohn's disease. Br J Surg 1997 Nov; 84: 1493-502
78. Blackburn WD. Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities. Am J Med 1996 Feb 26; 100 Suppl. 2A: 24A-30S
79. Ahern MJ, Chandran G. Category III symptom-modifying antirheumatic drugs: a comparative review. Clin Immunother 1995 Mar; 3: 196-217
80. Firestein GS, Zvaifler NJ. Anticytokine therapy in rheumatoid arthritis. N Engl J Med 1997 Jul 17; 337 (3): 195-7
81. Delemarre JBVM. What is new in the treatment of perianal fistulae in Crohn's disease. Neth J Med 1996; 48: 74-6
82. Hinterleitner TA, Petritsch W, Aichbichler H, et al. Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease. J Gastroenterol 1997; 35 (8): 603-8
83. Elton E, Hanauer SB. The medical management of Crohn's disease. Aliment Pharmacol Ther 1996 Feb; 10: 1-22
84. Egan LJ, Sandborn WJ, Tremaine SJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol 1998 Mar; 93 (3): 442-8
85. Tremaine WJ. Refractory IBD: medical management. Neth J Med 1997 Feb; 50: S12-4
86. Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Dig Dis Sci 1985 Jan; 30 (1): 58-64
87. Stack WA, Mann SD, Roy AJ. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997 Feb 22; 349: 521-4
88. Camussi G, Lupia E. The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis Drugs 1998 May; 55 (5): 613-20
89. Murray KM, Dahl SL. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Ann Pharmacother 1997 Nov; 31: 1335-8
90. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)- Fc fusion protein. N Engl J Med 1997 Jul 17; 337 (3): 141-7
91. Robinson M. Optimizing therapy for inflammatory bowel disease. Am J Gastroenterol 1997 Dec; 92 Suppl.: 12S-7S
92. Hawkey CJ, Stack WA. Chimeric monoclonal antibody cA2 to tumor necrosis factor-α for Crohn's disease [letter]. N Engl J Med 1998 Jan 29; 338: 333-4
93. Rutgeerts PJ. Prevention of early recurrence of Crohn's disease after ileal resection with ileocolonic anastomosis. Eur J Gastroenterol Hepatol 1994; 6 (2): 113-6
94. Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 1994 Feb; 39 (2): 374-80
95. Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol 1993; 88 (5): 646-9
96. Feagan BG, Rochon J, Fedorak RN. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995 Feb 2; 332: 292-7